“…In this investigation, DCM was defined as systolic dysfunction [left ventricular ejection fraction (LVEF) < 45%] with ventricular dilation [left ventricular end-diastolic diameter (LVEDD) > 55 mm] in the absence of an apparent secondary cause of cardiomyopathy, such as coronary heart disease, hypertensive heart disease, or valvular heart disease [20]. The exclusion criteria included ischaemic cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease, a history of uncontrollable or untreated hypertension for at least a year before the documentation of LV Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry dysfunction, and other secondary cardiomyopathies such as sarcoidosis and amyloidosis, the presence of significant coronary artery stenosis on angiography and non-ischaemic DCM secondary to valvular heart disease, systemic hypertension, cardiac surgery or acute myocarditis, excessive alcohol abuse, pregnancy, endocrine disease, active infectious disease or collagen disease, medical history of autoimmune disease [12,21]. All subjects gave written informed consent and the protocol was reviewed.…”